로딩 중…
지수 로딩 중…
LENZ Therapeutics, Inc.
LENZ· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$3.05+0.00%
2026-11-02
Financials
Valuation Metrics
LENZ Therapeutics, Inc.'s Market Cap is $96M. At end of 2025 it was $457M. Ranked #3055 of 3,116 in US market (top 98%), #1418 of 1,472 on NASDAQ (top 96%), #259 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $96M | US#3,055/3,116 Sec#259/265 |
| Revenue | $21M | US#2,786/3,116 Sec#160/265 |
| Net Income | $-126M | US—/3,116 Sec—/265 |
| Total Assets | $237M | US#2,955/3,116 Sec#235/265 |
| Net Assets | $219M | US#2,639/3,116 Sec#180/265 |
| Employees | 152 | US#2,530/3,116 Sec#143/265 |
| Value | ||
| P/B | 0.44x | US#92/3,116 Sec#4/265 |
| P/S | 4.45x | US#2,308/3,116 Sec#79/265 |
| FCF Yield | -119.65% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -57.47% | US#2,701/3,116 Sec#168/265 |
| ROA | -53.26% | US#2,995/3,116 Sec#221/265 |
| Op. Margin | -631.70% | US#2,786/3,116 Sec#156/265 |
| Revenue Growth | 329.50% | US#38/3,116 Sec#17/265 |
| Financial Health | ||
| Debt Ratio | 7.91% | US#77/3,116 Sec#36/265 |
| Total Debt | $122000.00 | US#3,002/3,116 Sec#257/265 |
| FCF | $-114M | US#2,659/3,116 Sec#156/265 |
| Cash | $24M | US#2,809/3,116 Sec#251/265 |
| Current Ratio | 13.55x | US#182/3,116 Sec#56/265 |
| Performance | ||
| 1Y Return | -89.74% | US#3,111/3,116 Sec#262/265 |
| 1M Return | -14.80% | US#2,551/3,116 Sec#189/265 |
| From 52W High | -92.90% | US#3,115/3,116 Sec#262/265 |
| 1Y MDD | -92.71% | US#3,114/3,116 Sec#262/265 |
| Trading | ||
| Volume | 2,256,540 shares | US#307/3,116 Sec#24/265 |
| Trading Value | $7M | US#1,884/3,116 Sec#145/265 |
| Per Share | ||
| EPS | $-4.02 | US—/3,116 Sec—/265 |
| BPS | $6.99 | US#2,081/3,116 Sec#99/265 |
Company Info
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.